Allan Reine - 17 Jan 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Chief Financial Officer
Signature
/s/ Marishka DeToy, attorney-in-fact
Issuer symbol
PRME
Transactions as of
17 Jan 2024
Net transactions value
$0
Form type
4
Filing time
19 Jan 2024, 16:19:41 UTC
Previous filing
17 Jan 2024
Next filing
21 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +600,000 $0.000000 600,000 17 Jan 2024 Common Stock 600,000 $6.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on January 17, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.